This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104: 2807-16. 10.1038/bjc.2012.483PalT.Permuth-WeyJ.BettsJA.KrischerJP.FioricaJ.ArangoH.et al.BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma casesCancer200510428071610.1038/bjc.2012.483351668223099806Open DOISearch in Google Scholar
Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, et al. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 2008; 108: 433-7. 10.1016/j.ygyno.2007.09.035BrozekI.OchmanK.DebniakJ.MorzuchL.RatajskaM.StepnowskaM.et al.High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in PolandGynecol Oncol2008108433710.1016/j.ygyno.2007.09.03517997147Open DOISearch in Google Scholar
Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009; 3: 138-50. 10.1016/j.molonc.2009.02.001RamusSJ.GaytherSA.The contribution of BRCA1 and BRCA2 to ovarian cancerMol Oncol200931385010.1016/j.molonc.2009.02.001552788919383375Open DOISearch in Google Scholar
Soegaard M, Kruger Kjaer S, Cox M, Wozniak E, H⊘´ $\mathop {\acute\oslash}$ gdall E, H⊘´ $\mathop {\acute\oslash}$ gdall C, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 2008; 14: 3761-7. 10.1158/1078-0432SoegaardM.Kruger KjaerS.CoxM.WozniakE.H⊘gdallE.H⊘gdallC.et al.BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from DenmarkClin Cancer Res2008143761710.1158/1078-0432Open DOISearch in Google Scholar
Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer 2010; 20: 704-16. 10.1111/IGC.0b013e3181dbd1a5TrainerAHMeiserB.WattsK.MitchellG.TuckerK.FriedlanderM.Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancerInt J Gynecol Cancer2010207041610.1111/IGC.0b013e3181dbd1a520973257Open DOISearch in Google Scholar
Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121: 353-7. 10.1016/j. ygyno.2011.01.020ZhangS.RoyerR.LiS.McLaughlinJR.RosenB.RischHA.et al.Frequencies of BRCA1 and BRCA2 mutations among 1342 unselected patients with invasive ovarian cancerGynecol Oncol2011121353710.1016/j. ygyno.2011.01.020Open DOISearch in Google Scholar
Krajc M, De Greve J, Goelen G, Teugels E. BRCA2 founder mutation in Slovenian breast cancer families. Eur J Hum Genet 2002, 10: 879-82. 10.1038/sj.ejhg.5200886KrajcM.De GreveJ.GoelenG.TeugelsE.BRCA2 founder mutation in Slovenian breast cancer familiesEur J Hum Genet2002108798210.1038/sj.ejhg.520088612461697Open DOISearch in Google Scholar
Krajc M, Teugels E, Žgajnar J, Goelen G, Bešić N, Novaković S, et al. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 2008; 9: 83. 10.1186/1471-2350-9-83KrajcM.TeugelsE.ŽgajnarJ.GoelenG.BešićN.NovakovićS.et al.Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer familiesBMC Med Genet200898310.1186/1471-2350-9-83254709618783588Open DOISearch in Google Scholar
Stegel V, Krajc M, Žgajnar J, Teugels E, De Greve J, Hočevar M, et al. The occurence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet 2011, 12: 9. 10.1186/1471-2350-12-9StegelV.KrajcM.ŽgajnarJ.TeugelsE.De GreveJ.HočevarM.et al.The occurence of germline BRCA1 and BRCA2 sequence alterations in Slovenian populationBMC Med Genet201112910.1186/1471-2350-12-9302593921232165Open DOISearch in Google Scholar
Cvelbar M, Hočevar M, Vidmar G, Teugels E. BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer. Neoplasma 2011; 58: 198-204. 10.4149/neo_2011_03_198CvelbarM.HočevarM.VidmarG.TeugelsE.BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancerNeoplasma20115819820410.4149/neo_2011_03_19821391735Open DOISearch in Google Scholar
Novaković S, Milatović M, Cerkovnik P, Stegel V, Krajc M, Hočevar M, et al. Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. Int J Oncol 2012, 41: 1619-27. 10.3892/ ijo.2012.1595NovakovićS.MilatovićM.CerkovnikP.StegelV.KrajcM.HočevarM.et al.Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer familiesInt J Oncol20124116192710.3892/ ijo.2012.1595Open DOISearch in Google Scholar
Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešić N, et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. Clin Genet 2014; 85: 59-63. 10.1111/cge.12119KrajcM.ZadnikV.NovakovićS.StegelV.TeugelsE.BešićN.et al.Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screeningClin Genet201485596310.1111/cge.1211923397983Open DOISearch in Google Scholar
Bešić N, Cernivc B, de Gréve J, Lokar K, Krajc M, Novaković S, et al. BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test 2008; 12: 203-9. 10.1089/gte.2007.0071BešićN.CernivcB.de GréveJ.LokarK.KrajcM.NovakovićS.et al.BRCA2 gene mutations in Slovenian male breast cancer patientsGenet Test200812203910.1089/gte.2007.007118439106Open DOISearch in Google Scholar
Krajc M, Blatnik A, Stegel V, Cerkovnik P, Škof E, Novaković S. BRCA status in ovarian cancer patients predicts therapeutic approach – first results. In: Writzl K, Teran N, Maver A, editors. 6thsymposium of the Slovenian Association of Medical Genetics. Gene editing technology: applications and societal implications. Book of abstracts; 2016 Apr 22; Ljubljana, Slovenia. Ljubljana: Slovenian Association of Medical Genetics, Slovenian Medical Association; 2016. p. 19.KrajcM.BlatnikA.StegelV.CerkovnikP.ŠkofE.NovakovićS.BRCA status in ovarian cancer patients predicts therapeutic approach – first resultsWritzlK.TeranN.MaverA.6thsymposium of the Slovenian Association of Medical Genetics. Gene editing technology: applications and societal implications.Book of abstracts2016 Apr 22Ljubljana, SloveniaLjubljana: Slovenian Association of Medical Genetics. Slovenian Medical Association201619Search in Google Scholar
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654-63. 10.1200/ JCO.2011.39.8545AlsopK.FeredayS.MeldrumC.deFazioA.EmmanuelC.GeorgeJ.et al.BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study GroupJ Clin Oncol20123026546310.1200/ JCO.2011.39.8545Open DOISearch in Google Scholar
Girolimetti G., Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, et al. BRCA-associated ovarian cancer: From molecular genetics to risk management. Biomed Res Int 2014; 2014: 787143. 10.1155/2014/787143GirolimettiG.PerroneAM.SantiniD.BarbieriE.GuerraF.FerrariS.et al.BRCA-associated ovarian cancer: From molecular genetics to risk managementBiomed Res Int2014201478714310.1155/2014/787143412997425136623Open DOISearch in Google Scholar
Lakhani SR, Manek S, Penault-Lorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10: 2473-81. 10.1158/1078-0432.CCR-1029-3LakhaniSR.ManekS.Penault-LorcaF.FlanaganA.ArnoutL.MerrettS.et al.Pathology of ovarian cancers in BRCA1 and BRCA2 carriersClin Cancer Res20041024738110.1158/1078-0432.CCR-1029-3Open DOISearch in Google Scholar
Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am, Deck D, et al. Patients with double-primary tumors in the breast and ovary – clinical characteristics and BRCA1-2 mutations status. Gynecol Oncol 2000; 79: 74-8. 10.1006/ gyno.2000.5895FishmanA.DekelE.ChetritA.Lerner-GevaL.Bar-AmDeckD.et al.Patients with double-primary tumors in the breast and ovary – clinical characteristics and BRCA1-2 mutations statusGynecol Oncol20007974810.1006/ gyno.2000.5895Open DOISearch in Google Scholar
Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, et al. Germline BRCA1-2 mutations in Non-Ashkenazi families with double primary breast and ovarian cancer. Gynecol Oncol 2001; 83: 383-7. 10.1006/gyno.2001.6431SchorgeJO.MahoneyNM.MillerDS.ColemanRL.MullerCY.EuhusDM.et al.Germline BRCA1-2 mutations in Non-Ashkenazi families with double primary breast and ovarian cancerGynecol Oncol200183383710.1006/gyno.2001.643111606101Open DOISearch in Google Scholar
Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-47. 10.1158/1055-9965.EPI-11-0775MavaddatN.BarrowdaleD.AndrulisIL.DomchekSM.EcclesD.NevanlinnaH.et al.Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Cancer Epidemiol Biomarkers Prev2012211344710.1158/1055-9965.EPI-11-0775327240722144499Open DOISearch in Google Scholar
Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283: 2260-5.BoydJ.SonodaY.FedericiMG.BogomolniyF.RheiE.MarescoDL.et al.Clinicopathologic features of BRCA-linked and sporadic ovarian cancerJAMA20002832260510.1001/jama.283.17.226010807385Search in Google Scholar
Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathologic features. Virchows Arch 2012; 460: 237-49. 10.1007/s00428-012-1203-5PratJ.Ovarian carcinomas: five distinct diseases with different origins. genetic alterations. and clinicopathologic featuresVirchows Arch20124602374910.1007/s00428-012-1203-522322322Open DOISearch in Google Scholar
Rakar S, Štolfa A, Kovačič J. Ovarijski karcinom: današnje stanje in Perspektive. Zdrav Vestn 1994; 63: 569-71.RakarS.ŠtolfaA.KovačičJ.Ovarijski karcinom: današnje stanje in PerspektiveZdrav Vestn19946356971Search in Google Scholar
Cvelbar M, Kralj B. Zgodnje odkrivanje epitelnega karcinoma jajčnika. Zdrav Vestn 2001; 81-4.CvelbarM.KraljB.Zgodnje odkrivanje epitelnega karcinoma jajčnikaZdrav Vestn2001814Search in Google Scholar
Schwartz DR, Kardia SLR, Shedden KA, Kuick R, Michailidis G, Taylor JMG, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-9.SchwartzDR.KardiaSLR.SheddenKA.KuickR.MichailidisG.TaylorJMG.et al.Gene expression in ovarian cancer reflects both morphology and biological behavior. distinguishing clear cell from other poor-prognosis ovarian carcinomasCancer Res20026247229Search in Google Scholar
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-208. 10.1158/1078-0432TothillRW.TinkerAV.GeorgeJ.BrownR.FoxSB.LadeS.et al.Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcomeClin Cancer Res200814519820810.1158/1078-0432Open DOISearch in Google Scholar
Wickramanayake A, Bernier G, Pennil C, Casadei S, Agnew KJ, Stray SM, et al. Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Gynecol Oncol 2012; 127: 552-5. 10.1016/j.ygyno.2012.09.009WickramanayakeA.BernierG.PennilC.CasadeiS.AgnewKJ.StraySM.et al.Loss of function germline mutations in RAD51D in women with ovarian carcinomaGynecol Oncol2012127552510.1016/j.ygyno.2012.09.009390574422986143Open DOISearch in Google Scholar
